Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619420 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
A Phase 2 study of Alzheimer Disease and Dementia, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 523
- Enrollment target
- 20
- Study locations
NCT04619420: Active Phase 2 study of Alzheimer Disease and Dementia, sponsored by Janssen Research & Development.
NCT04619420 is a Phase 2 study of Alzheimer Disease and Dementia that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 523 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04619420, a Phase 2 study of Alzheimer Disease and Dementia, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 523 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Primary Outcome
The linear combination of the ADAS Cog13 and ADCS ADL MCI that serves as a composite of cognition and function (overall clinical status) of the participant and score range from 0 to 138 with lower scores indicating worse performance. The iADRS will be a combination of ADAS Cog13 (score 0 to 85, higher scores indicate worse cognitive performance) and ADCS-ADL MCI (yielding a score 0 to 53, lower scores indicate worse daily function).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-63733657
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- Brain Matters Research - Delray Beach
- Neuropsychiatric Research Center of SWFL - Fort Myers
- Clinical NeuroScience Solutions Inc - Jacksonville
- Alphab Global Research - Jupiter
- K2 Medical Research - Maitland
- Tandem Intermediate LLC - Maitland
- Merritt Island Medical Research, LLC - Merritt Island
- University of Miami Miller School of Medicine - Miami
- Miami Jewish Health System - Miami
California
- Irvine Clinical Research - Irvine
- University of California San Diego Medical Center - La Jolla
- University of California - Los Angeles - Los Angeles
- Stanford University Medical Center - Palo Alto
- Pacific Research Network Prn - San Diego
- Syrentis Clinical Research - Santa Ana
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- Dignity Health - Phoenix
Connecticut
- Yale University School Of Medicine - New Haven
District of Columbia
- Georgetown University Clinical Research Unit CRU - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2026-03-08 |
| Phase | Phase 2 |
What the registry record for NCT04619420 still lists
NCT04619420 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04619420 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04619420 about?
NCT04619420 is a clinical study titled "A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease". The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
What is the current status of trial NCT04619420?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 523 participants. The study started on 2021-01-06. Estimated completion is 2026-03-08.
What conditions does trial NCT04619420 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Dysfunction.
What interventions are being tested in trial NCT04619420?
The interventions under investigation include: Placebo (DRUG), JNJ-63733657 (DRUG).
Who is sponsoring clinical trial NCT04619420?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04619420 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04619420's enrollment target sits among peer trials
523 51st of 306 higher than 256 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI